Bank of New York Mellon’s Rocket Pharmaceuticals RCKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $889K | Buy |
259,809
+19,967
| +8% | +$66.4K | ﹤0.01% | 3438 |
|
|
2026
Q1 | $859K | Sell |
239,842
-11,120
| -4% | -$44.2K | ﹤0.01% | 3300 |
|
|
2025
Q4 | $881K | Buy |
250,962
+5,649
| +2% | +$19.3K | ﹤0.01% | 3315 |
|
|
2025
Q3 | $800K | Buy |
245,313
+13,327
| +6% | +$42K | ﹤0.01% | 3341 |
|
|
2025
Q2 | $568K | Buy |
231,986
+22,019
| +10% | +$112K | ﹤0.01% | 3439 |
|
|
2025
Q1 | $1.4M | Buy |
209,967
+15,785
| +8% | +$156K | ﹤0.01% | 2861 |
|
|
2024
Q4 | $2.44M | Buy |
194,182
+9,949
| +5% | +$150K | ﹤0.01% | 2666 |
|
|
2024
Q3 | $3.4M | Sell |
184,233
-55,644
| -23% | -$1.14M | ﹤0.01% | 2491 |
|
|
2024
Q2 | $5.16M | Buy |
239,877
+22,521
| +10% | +$517K | ﹤0.01% | 2330 |
|
|
2024
Q1 | $5.86M | Sell |
217,356
-15,134
| -7% | -$430K | ﹤0.01% | 2241 |
|
|
2023
Q4 | $6.97M | Sell |
232,490
-11,762
| -5% | -$260K | ﹤0.01% | 2198 |
|
|
2023
Q3 | $5M | Buy |
244,252
+43,754
| +22% | +$795K | ﹤0.01% | 2314 |
|
|
2023
Q2 | $3.98M | Sell |
200,498
-5,569
| -3% | -$113K | ﹤0.01% | 2449 |
|
|
2023
Q1 | $3.53M | Buy |
206,067
+16,599
| +9% | +$325K | ﹤0.01% | 2490 |
|
|
2022
Q4 | $3.71M | Buy |
189,468
+38,737
| +26% | +$713K | ﹤0.01% | 2511 |
|
|
2022
Q3 | $2.41M | Buy |
150,731
+12,906
| +9% | +$201K | ﹤0.01% | 2731 |
|
|
2022
Q2 | $1.9M | Buy |
137,825
+7,936
| +6% | +$94.6K | ﹤0.01% | 2857 |
|
|
2022
Q1 | $2.06M | Buy |
129,889
+308
| +0.2% | +$5.32K | ﹤0.01% | 2919 |
|
|
2021
Q4 | $2.83M | Sell |
129,581
-35,892
| -22% | -$979K | ﹤0.01% | 2780 |
|
|
2021
Q3 | $4.95M | Buy |
165,473
+8,164
| +5% | +$297K | ﹤0.01% | 2495 |
|
|
2021
Q2 | $6.97M | Buy |
157,309
+5,058
| +3% | +$220K | ﹤0.01% | 2330 |
|
|
2021
Q1 | $6.75M | Sell |
152,251
-1,553
| -1% | -$85.3K | ﹤0.01% | 2300 |
|
|
2020
Q4 | $8.44M | Buy |
153,804
+25,575
| +20% | +$932K | ﹤0.01% | 2088 |
|
|
2020
Q3 | $2.93M | Sell |
128,229
-2,003
| -2% | -$49.4K | ﹤0.01% | 2466 |
|
|
2020
Q2 | $2.73M | Buy |
130,232
+7,252
| +6% | +$131K | ﹤0.01% | 2506 |
|
|
2020
Q1 | $1.72M | Buy |
122,980
+4,431
| +4% | +$87.7K | ﹤0.01% | 2634 |
|
|
2019
Q4 | $2.7M | Buy |
118,549
+4,405
| +4% | +$73.6K | ﹤0.01% | 2640 |
|
|
2019
Q3 | $1.33M | Sell |
114,144
-5,698
| -5% | -$70.7K | ﹤0.01% | 3001 |
|
|
2019
Q2 | $1.8M | Buy |
119,842
+24,205
| +25% | +$422K | ﹤0.01% | 2852 |
|
|
2019
Q1 | $1.68M | Buy |
95,637
+6,478
| +7% | +$102K | ﹤0.01% | 2872 |
|
|
2018
Q4 | $1.32M | Buy |
89,159
+10,764
| +14% | +$179K | ﹤0.01% | 2947 |
|
|
2018
Q3 | $1.93M | Buy |
78,395
+7,944
| +11% | +$172K | ﹤0.01% | 2848 |
|
|
2018
Q2 | $1.38M | Buy |
70,451
+59,354
| +535% | +$1.12M | ﹤0.01% | 3062 |
|
|
2018
Q1 | $208K | Buy |
11,097
+6,409
| +137% | +$105K | ﹤0.01% | 3922 |
|
|
2017
Q4 | $49K | Buy |
4,688
+800
| +21% | +$7.93K | ﹤0.01% | 4210 |
|
|
2017
Q3 | $28K | Sell |
3,888
-2,370
| -38% | -$10.8K | ﹤0.01% | 4185 |
|
|
2017
Q2 | $48K | Sell |
6,258
-7,907
| -56% | -$59K | ﹤0.01% | 4138 |
|
|
2017
Q1 | $114K | Sell |
14,165
-3,058
| -18% | -$20.6K | ﹤0.01% | 4001 |
|
|
2016
Q4 | $420K | Buy |
17,223
+1,282
| +8% | +$36.6K | ﹤0.01% | 3660 |
|
|
2016
Q3 | $605K | Sell |
15,941
-1,767
| -10% | -$55.6K | ﹤0.01% | 3443 |
|
|
2016
Q2 | $526K | Buy |
17,708
+9,466
| +115% | +$333K | ﹤0.01% | 3513 |
|
|
2016
Q1 | $244K | Buy |
8,242
+3,754
| +84% | +$113K | ﹤0.01% | 3715 |
|
|
2015
Q4 | $203K | Hold |
4,488
| – | – | ﹤0.01% | 3865 |
|
|
2015
Q3 | $169K | Buy |
+4,488
| New | +$206K | ﹤0.01% | 3961 |
|
Other funds holding RCKT
MAM
PFM
HWAM
AC
Bank of New York Mellon's RCKT Position: Q2 2026 in Review
Bank of New York Mellon increased its Rocket Pharmaceuticals (RCKT) stake by 8.3% in Q2 2026, buying an estimated $66.4K and bringing the position to 259,809 shares worth $889K. The position accounts for ﹤0.01% of the portfolio, ranked #3438.
Bank of New York Mellon first reported a position in RCKT in Q3 2015 and has held it in 44 quarters since. The position peaked at $8.44M in Q4 2020. 64 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.
- Bank of New York Mellon held 259,809 shares of Rocket Pharmaceuticals worth $889K as of Q2 2026.
- Bank of New York Mellon bought 19,967 Rocket Pharmaceuticals shares in Q2 2026, an estimated $66.4K.
- Rocket Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3438 holding.
- Bank of New York Mellon first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 44 quarters since.
- Bank of New York Mellon's Rocket Pharmaceuticals position peaked at $8.44M in Q4 2020.
- 64 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.